ERBB2 and gastroesophageal junction adenocarcinoma: In a randomized phase III study, pertuzumab mAb, which is directed against HER-2, in combination with trastuzumab, 5-fluorouracil, capecitabine, and cisplatin is currently investigated in patients with HER-2-positive metastatic gastric or GEJ adenocarcinoma (NCT01774786).